EICHOR
● Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Condition: Relapsed B Acute Lymphoblastic Leukaemia · Refractory B Acute Lymphoblastic Leukaemia · Sponsor: National University of Malaysia
About this study
This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
This description comes directly from the study's public registry record.
Talk to the study team
S Fadilah Abdul Wahid, MD, DrIntMed, PhD · +60391456450 · sfadilah@ppukm.ukm.edu.my
Always discuss trial participation with your own doctor first.
Locations (1)
| UKM Medical Centre | Bandar Tun Razak, Kuala Lumpur, Malaysia | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03937544